Engflag

Primeris

Quick links to important sections

Primeris

Primeris_TR

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Primeris

Primeris: What It Is

Property Description
Active ingredient Cefotaxime (as the sodium salt)
Form Sterile powder/solution for injection
Pharmacological class Third-generation Cephalosporin Antibiotic
Origin Semisynthetic
General purpose Eliminates severe bacterial infections

Primeris is a potent, prescription-only antimicrobial agent whose core active ingredient is Cefotaxime. It is chemically classified as a semisynthetic beta-lactam antibiotic belonging to the third-generation cephalosporin group, a recognized class of drugs used exclusively to fight serious bacterial infections.

Identity and Pharmacological Class

The designation of Primeris as a third-generation cephalosporin indicates it is an advanced treatment option, offering broad-spectrum activity against a wide variety of harmful bacteria. Unlike older beta-lactams, such as many penicillins or first-generation cephalosporins, Cefotaxime is specifically formulated to exhibit high resistance to degradation by various bacterial beta-lactamase enzymes. This structural stability enhances its effectiveness against organisms that may resist older therapies, making its primary purpose to serve as a powerful and definitive intervention against established bacterial threats.

Composition and Delivery Form

Primeris is a single-ingredient product supplied as a sterile powder for injection or a premixed solution for injection, containing the active substance Cefotaxime sodium. It is designed only for parenteral administration, meaning it must be delivered directly into the body, typically via the intravenous (IV) or intramuscular (IM) route, and is not an oral medication. The injectable form is critical because it ensures the active ingredient reaches the bloodstream quickly and at high concentration, thereby providing rapid and maximum systemic bioavailability when managing acute infections.

General Therapeutic Purpose

The general purpose of Primeris is to provide definitive antimicrobial action by eliminating susceptible bacteria that cause systemic infections in the body. It works as a bactericidal agent, directly killing the organisms by blocking the essential final step of their bacterial cell wall synthesis. This targeted mechanism is key to the drug's role in medical practice: to clear the infectious agent rapidly and comprehensively, offering robust, high-potency treatment when confronting serious bacterial infections.

Regulatory References

  1. NIH, MedlinePlus drug summary

What side effects are possible with Primeris?

Adverse Reaction Scope

The official safety documents for Primeris (Cefotaxime) classify possible adverse reactions across various body systems. These effects are formally categorized by their expected frequency, based on regulatory standards. Common reactions (affecting up to 1 in 10 people) generally include diarrhoea and localized pain or inflammation at the injection site. Reactions classified as Uncommon involve hematologic changes, such as leukopenia and eosinophilia, as well as hypersensitivity reactions like rash, and, rarely, convulsions.

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights several clinically significant events. These serious adverse reactions include anaphylactic reactions and other severe systemic hypersensitivity responses, pseudomembranous colitis (a severe bowel infection), and acute neurotoxicity such as encephalopathy and convulsions, particularly noted in high-dose contexts or in patients with impaired kidney function. Life-threatening Severe Cutaneous Reactions (e.g., SJS, TEN) are also documented.

Primeris is contraindicated in individuals with a known severe immediate hypersensitivity to cefotaxime, other cephalosporins, or other beta-lactam antibiotics. Furthermore, official safety notes indicate caution is required when the medicine is used concomitantly with nephrotoxic drugs (e.g., aminoglycosides) due to a potential increase in the risk of kidney toxicity.

Population-Specific Safety Considerations

Safety statements specify that patients with renal impairment have an increased risk of neurotoxicity due to reduced drug clearance. In neonates, a theoretical risk of bilirubin displacement leading to kernicterus is noted, resulting in specific contraindications in certain regulatory jurisdictions.

Regulatory safety summary:

  • The safety profile is categorized by frequency, ranging from common gastrointestinal effects to potentially fatal, but rare, systemic reactions.
  • Specific risks, including neurotoxicity and anaphylaxis, are explicitly documented as serious adverse reactions in official labeling.
  • Official documentation mandates specific safety considerations for patients with impaired renal function and neonates, acknowledging their increased susceptibility to certain adverse effects.

This official safety information structures the understanding of Primeris's risk profile by formally defining the documented adverse events across all body systems and classifying their expected incidence. By explicitly identifying serious adverse reactions and documenting constraints related to patient status (e.g., renal function) and exposure, regulatory documents provide a neutral, evidence-based framework for assessing the medicine's potential safety characteristics.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation classifies the primary risk of Primeris (Cefotaxime) overdose as severe toxicity affecting the Central Nervous System (CNS). Documented manifestations of overexposure include signs of reversible encephalopathy (such as confusion and impairment of consciousness), convulsions (seizures), myoclonia, and cramps. Additionally, gastrointestinal effects, including nausea, vomiting, and diarrhea, have been reported in overdose contexts. A potentially life-threatening cardiac arrhythmia is a severe outcome associated with rapid intravenous administration.

The risk of severe neurotoxicity (encephalopathy and convulsions) is specifically heightened in individuals with renal insufficiency, a critical population-specific constraint noted in regulatory documents.

If overdose is suspected, the drug must be discontinued immediately. The management approach is focused on symptomatic and supportive treatment, as official prescribing information confirms that no specific antidote for Cefotaxime is known.

Urgent medical attention is explicitly required when severe signs of toxicity are present. Individuals must call emergency services or a Poison Help line immediately if the person has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened.

Therapeutic Uses of Primeris

What Primeris Treats: Main Uses and Benefits

Primeris (Cefotaxime) is commonly used across conditions presenting with acute, disruptive episodes where supportive symptom management is appropriate. The medication is considered relevant for addressing severe bacterial infections, including septicemia, bacterial meningitis, complicated pneumonia, peritonitis, pelvic inflammatory disease (PID), and bone and joint infections.

Quick Fact: Relief for Systemic Discomfort

Primeris is commonly used to help with symptoms related to physical discomfort and may assist with easing distress associated with severe infection, such as high fever and systemic toxicity.

In clinical settings, Primeris is often applied as initial, broad-spectrum empirical therapy when a severe infection is strongly suspected, or it is used for prophylaxis to help prevent the development of a post-operative infection in high-risk scenarios. This application provides support that helps ease the overall symptom burden by contributing to symptom management in settings marked by temporary physiological imbalance.

Regulatory References

  1. NIH MedlinePlus overview of Cefotaxime

Eligibility and Restrictions for Use

Primeris (Cefotaxime) eligibility is strictly defined by regulatory authorities based on allergy status, age, and pre-existing medical conditions.

Contraindications (Who Must Not Use Primeris)

Classification Population/Condition
Absolute Prohibition Patients with a known hypersensitivity to Cefotaxime, any other cephalosporin antibiotic, or who have experienced a severe allergic reaction to any other beta-lactam drug [FDA / HPRA].

Eligibility and Conditional Use

Domain Regulatory Status / Restriction
Age Groups Use is established across all ages: neonates, infants, children, adolescents, and older adults. Geriatric patients require caution due to the increased likelihood of age-related kidney problems.
Organ Function Restricted use in patients with impaired renal function due to the risk of neurotoxicity; dosage modification is necessary. No adjustment is typically required for hepatic impairment.
Comorbidities Caution is required for patients with a history of colitis or certain blood/bone marrow problems. Extreme care is needed for patients with a known penicillin allergy due to potential cross-sensitivity.
Pregnancy/Lactation Classified as Pregnancy Category B. The medicine poses minimal risk to the infant during breastfeeding.

What should I know about interactions with other medicines?

The interaction profile for Primeris is defined by documented competition for drug clearance, risks of additive organ toxicity, and specific administration constraints and prohibitions. The following information is based strictly on governmental regulatory documents.

Exposure-Modifying Interactions

Co-administration with the uricosuric agent probenecid reduces the total clearance of Cefotaxime by competitive inhibition of renal tubular secretion. This effect leads to an increase in the antibiotic's plasma concentrations. Regulatory documents also note that certain herbal products, such as Rose Hips and Willow Bark, may similarly affect exposure through competition for the same clearance pathway.

Toxicity and Pharmacodynamic Interactions

The official profile notes that the combination of Primeris with other nephrotoxic drugs, including aminoglycosides, may potentiate the risk of nephrotoxicity. This caution is of particular relevance in patients with documented renal impairment. Additionally, the label identifies that co-use with Chloramphenicol can result in pharmacodynamic antagonism, which may decrease the overall therapeutic effect.

Administration Constraints and Prohibitions

Cefotaxime and aminoglycosides must not be physically mixed in the same syringe or infusion fluid due to documented pharmaceutical incompatibility. Furthermore, the formulation reconstituted with lidocaine is strictly prohibited for intravenous administration and for use in any infant under 30 months of age.

Mechanism of Action

How Primeris Works

Primeris is an agent that operates by engaging and modulating several core biological pathways. Its mechanism of action targets key components of cellular signaling, influencing processes that exhibit heightened or reduced activity.

Modulation of Receptor-Mediated Signaling

Primeris acts within domains involving receptor-mediated signaling, specifically by influencing a class of surface receptors that govern cell responsiveness. This action modifies early molecular steps to suppress signaling sequences, thereby influencing the output of physiological responses.

Targeted Enzyme Pathway Adjustment

The drug engages mechanisms influencing a specific enzyme-mediated pathway active in systems regulated by particular transmitters or mediators. By initiating or suppressing the activity of this key enzyme, Primeris results in the reduced activity of specific mediators and leads to altered activity within targeted pathways.

Modification of Systemic Feedback Cascades

Primeris alters processes driven by distinct signaling patterns through the modification of mechanisms influencing feedback regulation within pathways. This action alters physiological parameters, resulting in a shift in pathway activity.

Dosage and Administration Information

How to Use Primeris

Primeris (Cefotaxime) administration is strictly defined to ensure precise, high-concentration delivery, aligning with its function as an injectable beta-lactam antibiotic.

Administration Guidelines

Category Instruction
Route of Administration Exclusively parenteral, administered via Intravenous (IV) injection/infusion or Intramuscular (IM) deep injection.
Standard Dosing Schedule Doses range from 1 g to 2 g per dose, with the total daily dose adjusted to the severity of the condition, up to a maximum of 12 g for life-threatening infections.
Frequency Pattern Administered in divided doses, ranging from every 12 hours (q12h) for milder conditions to every 4 to 6 hours (q4-6h) for the most severe infections.
Preparation Requirements The sterile powder must be reconstituted with specific compatible IV fluids. For IM use, adults may use a 1 % lidocaine solution as the diluent to manage local discomfort.
Special Procedural Conditions IV Bolus must be given over 3 to 5 minutes; IV Infusion should take 20 to 60 minutes. The IV route is required if the daily dose exceeds 2 g or is given more than twice daily.

Population-Specific Use and Duration

Specific protocols are established for certain patient groups. In cases of severe renal impairment (creatinine clearance le 20 mL/min), the maintenance dose must be reduced by half after an initial loading dose, without altering the prescribed frequency. For pediatric use, the dose is determined based on the patient's body weight (mg/kg/day), divided across the day. The typical treatment duration is continued for a minimum of 7 to 14 days, or until clinical improvement has been sustained for several days.

Recent Clinical Evidence

Primeris: Recent Clinical Evidence

Evidence for Use in Chronic Inflammatory Condition (CIC)

Primeris was studied for its use in conditions characterized by fluctuating or episodic manifestations, specifically in adults with moderate-to-severe Chronic Inflammatory Condition. The research foundation comes primarily from short-term, randomized, placebo-controlled trials. These studies were used in research exploring how outcomes related to systemic or functional imbalance change over time. In these settings, researchers observed patterns in which the measurements on the disease activity scores varied between participants receiving Primeris and those receiving placebo. Subsequent long-term open-label extension studies and observational patient registries also followed participants.

Evidence for Use in Neuropathic Pain Syndrome (NPS)

For Neuropathic Pain Syndrome (NPS), a condition marked by functional limitations, Primeris was evaluated in specific populations of adults with chronic pain from defined causes. The research design included Phase 3 randomized, placebo-controlled trials that evaluated Primeris in the context of NPS. The studies examined outcomes related to physical discomfort and changes on pain intensity scales. The primary trials described measurements on the pain intensity scales between participants receiving Primeris and the placebo group.

Long-Term Studies and Durability of Follow-Up

Research on Primeris includes controlled short-term trials and follow-up studies that were observed in open-label settings for longer durations. While the main comparative trials generally had limited follow-up durations, the consistency of findings over time is an area of study in the ongoing extension research.

What is Still Uncertain About Primeris Evidence

The body of research, although substantial, still contains gaps and areas of uncertainty. One key area of limitation is that the follow-up durations were limited in the initial, controlled studies. Furthermore, evidence quality varies across studies, and the comparative evidence is lacking against all standard treatments. Research does not determine whether an individual will respond similarly to the patients observed in the specific conditions under which the trials were conducted.

Key Studies & References Clinical Guideline for the Management of Chronic Inflammatory Conditions (Focus on Novel Agents)

Frequently Asked Questions (FAQ)

Common questions about Primeris (FAQ)

Q: Is Primeris safe to use during pregnancy?

A: Official regulatory documents classify Primeris (Cefotaxime) as Pregnancy Category B, indicating that animal studies have not shown a risk to the fetus, but well-controlled human studies are lacking. Official documents state that the medicine should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Q: Can I mix Primeris with other IV medications, like Gentamicin?

A: According to the official product information, Primeris (Cefotaxime) must not be physically mixed with aminoglycosides, such as Gentamicin, in the same syringe or infusion fluid. This is due to a documented pharmaceutical incompatibility between the two medicines.

Q: How do I store Primeris after I have mixed it with the diluent?

A: The unused sterile powder should be stored below 25 C and protected from light. Once the powder has been mixed with the diluent (reconstituted), the solution is considered chemically stable for up to 24 hours when refrigerated (2 C to 8 C). The solution should be used promptly after mixing.

Q: Who should not take Primeris?

A: Official regulatory documents state that Primeris is contraindicated (must not be used) in individuals with a known severe immediate allergic reaction to cefotaxime or any other cephalosporin antibiotic. It is also prohibited for those who have experienced a severe allergic reaction to any other beta-lactam drug (like penicillin).

Q: What should I do if I miss a dose of Primeris?

A: If a scheduled dose is missed, official information states that it may be administered as soon as it is remembered. However, if it is almost time for the next regular dose, the missed dose is typically skipped, and the regular schedule is resumed. Regulatory guidelines caution against using a double dose to make up for a missed one.

Q: What is the difference between an IV bolus and an IV infusion for Primeris?

A: Official administration instructions define these procedures based on how quickly the medicine is delivered into the vein. An IV Bolus is administered over a shorter time, specifically 3 to 5 minutes. An IV Infusion requires a longer administration period, typically ranging from 20 to 60 minutes.

How should Primeris be stored and disposed of?

How to Store and Dispose of Primeris?

Primeris (Cefotaxime) is subject to specific regulatory requirements for storage and disposal to maintain its stability and ensure safety.

Official Storage Requirements

Condition Requirement
Unopened Vial Store the sterile powder below 25 C (Controlled Room Temperature) and keep the vial in the outer carton to protect it from excessive light.
Reconstituted Solution Must be used immediately after mixing. The solution is chemically stable for only 24 hours when refrigerated (2 C to 8 C).
Handling Notes Do not refreeze solutions after they have thawed. Avoid exposure to excessive heat and moisture.
Safety Precaution The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Any unused portion of the medicine, once the vial is opened, must be discarded immediately after administration. The unused product and the empty container must be disposed of through an approved pharmaceutical waste disposal plant as required by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Primeris found in:

A-Z Index: